ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Scope & Guideline
Pioneering Insights for Digestive Health Innovations
Introduction
Aims and Scopes
- Gastrointestinal and Liver Disease Research:
The journal covers a wide array of gastrointestinal and liver diseases, highlighting research on pathophysiology, diagnosis, and treatment options. - Pharmacotherapy and Treatment Strategies:
AP&T emphasizes the role of pharmacotherapy in managing gastrointestinal and liver diseases, including studies on drug efficacy, safety, and guidelines for clinical practice. - Emerging Therapies and Interventions:
The journal frequently publishes research on novel treatment modalities, including biologics, small molecules, and innovative therapies for various digestive disorders. - Clinical Guidelines and Best Practices:
AP&T aims to provide evidence-based recommendations for clinicians, focusing on improving patient outcomes in gastrointestinal and liver diseases. - Patient-Centered Outcomes and Quality of Life:
The journal addresses the importance of patient-reported outcomes, quality of life, and the psychosocial aspects of managing chronic digestive diseases. - Epidemiological Studies and Public Health:
Research related to the epidemiology of gastrointestinal and liver diseases, including risk factors, prevalence, and the impact of public health initiatives, is a key focus area. - Technology and Innovation in Gastroenterology:
AP&T explores advancements in diagnostic and therapeutic technologies, including the use of machine learning and non-invasive testing methods in gastroenterology.
Trending and Emerging
- Metabolic Dysfunction-Associated Liver Disease (MAFLD):
Research on MAFLD is increasingly prominent, focusing on its clinical implications, pathophysiology, and treatment strategies, reflecting a growing recognition of its significance. - Biologics and Targeted Therapies:
The use of biologics and targeted therapies for inflammatory bowel disease (IBD) and other gastrointestinal conditions is a rapidly expanding area of research, with a focus on optimizing treatment regimens. - Artificial Intelligence and Machine Learning:
The application of AI and machine learning in predicting disease outcomes and personalizing treatment approaches is a growing trend, indicating a shift towards data-driven medicine. - Patient-Centered Care and Quality of Life:
There is an increasing emphasis on research that evaluates patient-reported outcomes and quality of life in the context of gastrointestinal diseases, aligning with broader trends in healthcare. - Public Health and Epidemiology:
Studies addressing the epidemiology of liver diseases and gastrointestinal disorders, as well as public health interventions, are gaining traction, reflecting an awareness of the societal impact of these conditions. - Gut Microbiome Research:
The exploration of the gut microbiome’s role in health and disease, particularly in IBD and liver diseases, is an emerging theme, highlighting its significance in therapeutic strategies. - Long-term Outcomes of Chronic Diseases:
Research focusing on the long-term outcomes of chronic gastrointestinal and liver diseases, including the impact of treatment on disease progression and survival, is becoming increasingly important.
Declining or Waning
- Traditional Dietary Interventions:
Research focusing solely on traditional dietary interventions for gastrointestinal diseases has seen reduced emphasis, as newer therapies and pharmacological approaches gain prominence. - Basic Science without Clinical Relevance:
Studies that do not translate into clinical applications or lack direct relevance to patient care are being published less frequently, as the journal prioritizes clinically impactful research. - Single-Center Studies:
There is a noticeable decline in the publication of single-center studies, with a shift towards multi-center and larger cohort studies that yield more generalizable results. - Isolated Pathophysiological Mechanisms:
Research focusing solely on isolated mechanisms of disease without exploring therapeutic implications or clinical outcomes is diminishing, reflecting a preference for integrated approaches. - Non-Pharmacological Treatments:
There appears to be a waning interest in non-pharmacological treatments for digestive diseases, as the journal increasingly emphasizes pharmacotherapy and innovative drug treatments.
Similar Journals
Korean Journal of Gastroenterology
Pioneering Research for Better Gastrointestinal CareKorean Journal of Gastroenterology (ISSN: 1598-9992, E-ISSN: 2233-6869), published by the Korean Society of Gastroenterology, has been a premier outlet for research and advancements in the field of gastroenterology since its inception in 1968. This open-access journal, based in South Korea, fosters a global dialogue on gastrointestinal health, embracing contributions from a diverse array of disciplines within medicine. It is currently ranked in the Q4 quartile for miscellaneous medicine and holds a Scopus rank of #323 out of 636 in general medicine, reflecting its commitment to publishing impactful research despite its relatively recent establishment in high-impact metrics. With a continuous publication timeline extending through to 2024, the journal aims to enhance understanding of gastrointestinal disorders and promote innovative treatments, making it an essential resource for researchers, clinicians, and students alike who seek to stay abreast of the latest developments and clinical applications in gastroenterology.
Gastrointestinal Disorders
Connecting Researchers to Revolutionize Gastrointestinal CareGastrointestinal Disorders is a prominent open-access journal published by MDPI, based in Switzerland, that focuses on the latest research and innovations in the fields of gastroenterology, hepatology, and immunology. Since its inception in 2019, the journal has provided a vital platform for researchers and professionals to disseminate their findings, engaging with a global audience keen on advancing knowledge in gastrointestinal health. With a dedicated commitment to high-quality, peer-reviewed articles, Gastrointestinal Disorders has gained recognition in 2023, achieving Q3 status in gastroenterology and notable rankings in several other categories, including a respectable position in the quartiles for hepatology, immunology, and oncology. Despite its recent establishment, the journal has quickly become a valuable resource, facilitating open access to critical insights in the study of gastrointestinal diseases and their management, ensuring that emerging research is readily available to inform clinical practice and educate future professionals.
Annals of Gastroenterology
Fostering Excellence in Gastroenterological StudiesAnnals of Gastroenterology, published by the Hellenic Society of Gastroenterology, serves as a pivotal platform for advancing the field of gastroenterology, highlighting research that spans across the spectrum of gastrointestinal diseases and treatments. With an ISSN of 1108-7471 and E-ISSN of 1792-7463, this journal has established itself as a reputable source of scholarship since its inception in 2000, converging valuable insights through to 2024. Ranking within Q2 of its category and achieving a respectable 78th position out of 167 in the Scopus rankings, the journal holds a strong presence in the academic community, appealing to researchers, clinicians, and students alike. Although not an open access publication, Annals of Gastroenterology is dedicated to disseminating high-quality research that aids in the understanding and treatment of gastrointestinal conditions, making it an essential reference point for those engaged in this dynamic field.
PULMONARY PHARMACOLOGY & THERAPEUTICS
Connecting research to clinical excellence in pulmonary medicine.Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.
Hepatology Forum
Exploring breakthroughs in gastroenterology and hepatology.Hepatology Forum is an esteemed journal dedicated to disseminating cutting-edge research and insights in the fields of gastroenterology and hepatology. Published by KARE PUBL in Turkey, this journal serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to advance their knowledge and practices related to liver diseases and gastrointestinal disorders. With an ISSN of 1307-5888 and an E-ISSN of 2757-7392, it features peer-reviewed articles that encompass a wide range of topics from basic research to clinical applications. Although categorized in the Q3 quartile for both gastroenterology and hepatology in 2023, Hepatology Forum continues to show significant potential for growth and impact, as evidenced by its Scopus rankings. Through its commitment to open scientific exchange, the journal not only facilitates the sharing of innovative methodologies and findings but also fosters networking among professionals in the field. As it converges through the years from 2020 to 2024, Hepatology Forum remains an important resource for the advancement of liver health and diseases, appealing to both established experts and emerging scholars alike.
Hepatology International
Connecting experts to revolutionize liver health.Hepatology International is a premier academic journal dedicated to advancing the field of liver research and hepatology. Published by SPRINGER, this journal boasts a prestigious Q1 ranking in Hepatology as of 2023, underscoring its commitment to high-quality research dissemination. The journal’s scope encompasses a wide range of topics related to liver disease, including clinical, translational, and basic science studies. With its impact factor reflecting its relevance and influence in the field, Hepatology International serves as an essential resource for researchers, clinicians, and students aiming to keep abreast of the latest developments and breakthroughs. Though traditionally a subscription-based journal, it offers a vast array of insightful articles that contribute significantly to our understanding of hepatological conditions. The journal continues its trajectory of growth since its inception in 2008, anticipating a convergence of knowledge and innovation through to 2024. Located in the heart of New York City, this journal not only represents a crucial platform for global hepatology research but also fosters a collaborative community of experts dedicated to improving liver health worldwide.
Nature Reviews Gastroenterology & Hepatology
Transforming Research into Clinical PracticeNature Reviews Gastroenterology & Hepatology is a premier academic journal published by NATURE PORTFOLIO, specializing in the vital fields of gastroenterology and hepatology. With an impressive impact factor and categorized in Q1 for both disciplines, this journal ranks at the top of its field, with Scopus rankings placing it in the 99th percentile for gastroenterology and hepatology. The journal aims to provide critical reviews that synthesize the latest research findings, clinical practices, and breakthroughs, catering to researchers, healthcare professionals, and students alike. With its wide-ranging access options, it promotes the dissemination of knowledge essential for advancements in understanding digestive and liver disorders. The journal has been committed to academic excellence since its convergence in 2009, continuing to shape the future of gastroenterological and hepatological research through rigorous peer-reviewed content.
Gastroenterologia y Hepatologia
Empowering healthcare professionals with high-quality research.Gastroenterologia y Hepatologia, published by Elsevier España SLU, is a distinguished journal dedicated to advancing the fields of gastroenterology and hepatology. With a publication history spanning from 1982 to 2024, this journal is recognized for its commitment to disseminating high-quality research and reviews that address critical developments in the diagnosis and treatment of gastrointestinal and liver diseases. Although it currently ranks in the Q3 quartile in both gastroenterology and hepatology based on the 2023 metrics, the journal continues to attract a global audience of researchers, healthcare professionals, and students eager to engage with the latest findings. The journal is accessible in both print and electronic formats (ISSN: 0210-5705), making its valuable insights reachable to a broad spectrum of subscribers. By fostering a platform for rigorous scholarly communication, Gastroenterologia y Hepatologia plays a vital role in shaping the future of research in these essential medical fields.
DIGESTIVE AND LIVER DISEASE
Advancing knowledge in gastroenterology and hepatology.DIGESTIVE AND LIVER DISEASE is a prominent journal published by Elsevier Science Inc, dedicated to advancing the field of gastroenterology and hepatology. With an ISSN of 1590-8658 and an E-ISSN of 1878-3562, this journal has established itself as a significant resource within the academic community, especially considering its Q2 ranking in both gastroenterology and hepatology categories as of 2023. Spanning from 2000 to 2024, the journal presents a diverse array of peer-reviewed articles, clinical studies, and review papers that explore the latest advancements and research findings in digestive and liver diseases. The journal's robust impact, reflected in its Scopus rankings—40th out of 167 in gastroenterology and 28th out of 82 in hepatology—highlights its critical role in shaping practices and understanding in these vital areas of medicine. With open access options available, DIGESTIVE AND LIVER DISEASE aims to make high-quality research accessible to a wider audience, thereby encouraging collaboration and innovation. Researchers, healthcare professionals, and students alike will find valuable insights into the complex mechanisms, diagnostics, and therapeutic strategies pertinent to digestive and liver health.
Journal of Gastrointestinal and Liver Diseases
Unveiling the Latest in Gastrointestinal and Liver DiseasesThe Journal of Gastrointestinal and Liver Diseases, published by MEDICAL UNIV PRESS in Romania, serves as a pivotal platform for the dissemination of significant research in the fields of gastroenterology and hepatology. Established in 2006, this journal has evolved over the years, currently holding a Q3 rank in Gastroenterology and a Q2 rank in Medicine (miscellaneous), reflecting its commitment to high-quality scholarship and impactful contributions to medical science.
With an ISSN of 1841-8724 and an E-ISSN of 1842-1121, the journal engages a diverse readership of researchers, clinicians, and students passionate about advancing knowledge in gastrointestinal and liver health. While it currently does not operate under an open access model, the journal remains a vital resource for those seeking to stay updated on the latest developments and emerging trends in the field. As it converges towards a broader impact, projected through its coverage until 2024, the Journal of Gastrointestinal and Liver Diseases continues to contribute to the academic landscape, encouraging innovation and comprehensive understanding in digestive health.